Friday, October 02, 2015 11:14:22 PM
Please provide specific evidence of this claim.
The stock sales are listed in the quarterly and annual reports, as are the sales of product and the costs of manufacturing and distribution etc. How, exactly, in light of that, is the company making money from selling stock, any more than to meet expenses and production of Sucanon for distribution? What, exactly, is the evidence for the previous claim that "hundreds of millions of shares printed at zero cost basis" when at last report some 317 million shares total were outstanding? Where is the "pump" claimed so vividly? The promoters?
If the FDA application was just for a news release, where was the dilution of dump surrounding that announcement? For that matter, why put out information for a "pump" that states the company cannot sell Sucanon in the US as a Neutraceutical? While the acknowledgment that Sucanon should be considered a drug for US application, that cuts both ways in that a significant expense would be required to bring it to market. Not IMO a piece of news that will cause an immediate unjustified spike in stock price.
I have laid out my argument with the science of Sucanon studies. Let's see some cold hard facts on the above so they can be evaluated by any here that are interested
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM